Vanguard Group Inc. increased its holdings in Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) by 13.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 560,616 shares of the company’s stock after buying an additional 65,960 shares during the period. Vanguard Group Inc.’s holdings in Palvella Therapeutics were worth $58,680,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently modified their holdings of PVLA. Archer Investment Corp bought a new position in shares of Palvella Therapeutics in the third quarter valued at approximately $28,000. Russell Investments Group Ltd. bought a new position in shares of Palvella Therapeutics in the third quarter valued at approximately $36,000. JPMorgan Chase & Co. grew its holdings in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Palvella Therapeutics in the second quarter valued at approximately $85,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Palvella Therapeutics in the second quarter valued at approximately $104,000. 40.11% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Chardan Capital upped their target price on Palvella Therapeutics from $210.00 to $240.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a report on Tuesday, February 24th. HC Wainwright upped their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, BTIG Research upped their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $199.53.
Insider Buying and Selling at Palvella Therapeutics
In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elaine J. Heron acquired 2,400 shares of Palvella Therapeutics stock in a transaction on Friday, February 27th. The shares were purchased at an average cost of $125.00 per share, with a total value of $300,000.00. Following the completion of the acquisition, the director owned 47,812 shares of the company’s stock, valued at $5,976,500. This trade represents a 5.28% increase in their position. The SEC filing for this purchase provides additional information. 20.50% of the stock is owned by corporate insiders.
Palvella Therapeutics Trading Down 4.0%
Shares of NASDAQ PVLA opened at $114.24 on Friday. The stock has a fifty day simple moving average of $124.49 and a two-hundred day simple moving average of $104.18. Palvella Therapeutics, Inc. has a 1-year low of $20.20 and a 1-year high of $151.18. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -27.40 and a beta of -0.13.
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Analysts forecast that Palvella Therapeutics, Inc. will post -5.43 EPS for the current year.
Palvella Therapeutics Company Profile
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Read More
- Five stocks we like better than Palvella Therapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report).
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
